TY - JOUR
T1 - Metabolism of glutamine in lymphocytes
AU - Brand, Karl
AU - Fekl, Werner
AU - von Hintzenstern, Jutta
AU - Langer, Klaus
AU - Luppa, Peter
AU - Schoerner, Christoph
N1 - Funding Information:
From the Institute of Biochemistry, Medical Faculty, University of Erlangen-Nuremberg, FRG. and the Research Institute for Experimental Nutrition eV, Erlangen, FRG. Supported in part by the Jacques Pfrimmer-Gediichtnissttftung, Erlangen, FRG. Address reprint requests to Karl Brand, Institute of Biochemistry, Medical Faculty, Fahrstrasse 17, D 8520 Erlangen, FRG. o I989 by Grune & Stratton, Inc. 00260495/89/3808-1006$03.00/O
PY - 1989/8
Y1 - 1989/8
N2 - Pathways of glutamine metabolism in resting and proliferating rat thymocytes and established human T- and B-lymphoblastoid cell lines were evaluated by in vitro incubations of freshly prepared or cultured cells for one to two hours with [U14C]glutamine. Complete recovery of glutamine carbons utilized in products allowed quantification of the pathways of glutamine metabolism under the experimental conditions. Partial oxidation of glutamine via 2-oxoglutarate in a truncated citric acid cycle to CO2 and oxaloacetate, which then was converted to aspartate, accounted for 76% and 69%, respectively, of the glutamine metabolized beyond the stage of glutamate by resting and proliferating thymocytes. Similar results were obtained with the lymphoblastoid T- and B-cell lines. Complete oxidation to CO2 in the citric acid cycle via 2-oxoglutarate dehydrogenase and isocitrate dehydrogenase accounted for only 25% and 7%, respectively. In proliferating cells a substantial amount of glutamine carbons was also recovered in pyruvate, alanine, and especially lactate. The main route of glutamine and glutamate entrance into the citric acid cycle via 2-oxoglutarate in lymphocytes appears to be transamination by aspartate aminotransferase rather than oxidative deamination by glutamate dehydrogenase. In the presence of glucose as a second substrate, glutamine utilization and aspartate formation markedly decreased, but complete oxidation of glutamine carbons to CO2 increased to 37% and 23%, respectively, in resting and proliferating cells. The dipeptide, glycyl-l-glutamine, which is more stable than free glutamine, can substitute for glutamine in thymocyte cultures at higher concentrations.
AB - Pathways of glutamine metabolism in resting and proliferating rat thymocytes and established human T- and B-lymphoblastoid cell lines were evaluated by in vitro incubations of freshly prepared or cultured cells for one to two hours with [U14C]glutamine. Complete recovery of glutamine carbons utilized in products allowed quantification of the pathways of glutamine metabolism under the experimental conditions. Partial oxidation of glutamine via 2-oxoglutarate in a truncated citric acid cycle to CO2 and oxaloacetate, which then was converted to aspartate, accounted for 76% and 69%, respectively, of the glutamine metabolized beyond the stage of glutamate by resting and proliferating thymocytes. Similar results were obtained with the lymphoblastoid T- and B-cell lines. Complete oxidation to CO2 in the citric acid cycle via 2-oxoglutarate dehydrogenase and isocitrate dehydrogenase accounted for only 25% and 7%, respectively. In proliferating cells a substantial amount of glutamine carbons was also recovered in pyruvate, alanine, and especially lactate. The main route of glutamine and glutamate entrance into the citric acid cycle via 2-oxoglutarate in lymphocytes appears to be transamination by aspartate aminotransferase rather than oxidative deamination by glutamate dehydrogenase. In the presence of glucose as a second substrate, glutamine utilization and aspartate formation markedly decreased, but complete oxidation of glutamine carbons to CO2 increased to 37% and 23%, respectively, in resting and proliferating cells. The dipeptide, glycyl-l-glutamine, which is more stable than free glutamine, can substitute for glutamine in thymocyte cultures at higher concentrations.
UR - http://www.scopus.com/inward/record.url?scp=0024383391&partnerID=8YFLogxK
U2 - 10.1016/0026-0495(89)90136-4
DO - 10.1016/0026-0495(89)90136-4
M3 - Article
C2 - 2569663
AN - SCOPUS:0024383391
SN - 0026-0495
VL - 38
SP - 29
EP - 33
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
IS - 8 SUPPL. 1
ER -